Press releases

2018-02-28 - 17:45

Genkyotex Announces 2017 Annual Financial Results

2018-02-20 - 18:00

Genkyotex's Lead Product Candidate, GKT831, Halts the Tumor Promoting Effect of Cancer Associated Fibroblasts

2018-01-31 - 18:00

Genkyotex reports December 31, 2017 cash position and provides business update

2017-12-21 - 18:00

Genkyotex announces its financial calendar for 2018

2017-10-26 - 18:00

Genkyotex provides business update for Q3 2017

2017-09-21 - 18:45

2017 first-half results

2017-08-03 - 17:45

Genkyotex’s GKT831 Shown to Delay Tumor Growth in Multiple Preclinical Models by Targeting Cancer Associated fibroblasts

2017-07-27 - 18:00

Genkyotex provides business update for Q2 2017

2017-06-28 - 18:00

Genkyotex Announces Investigator-Initiated Phase 2 Clinical Trial to Evaluate 48-week Treatment with GKT831 in Patients with Type 1 Diabetes and Kidney Disease

2017-06-27 - 18:00

Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 in Primary Biliary Cholangitis

2017-05-02 - 21:15

Genkyotex Announces FDA Approval of IND for Phase 2 Trial of GKT831 in Patients with Primary Biliary Cholangitis

2017-04-27 - 19:06

Genkyotex provides business update for Q1 2017

2017-03-14 - 18:00

Genkyotex to participate in the 1st Annual H.C. Wainwright NASH Investor Conference in New York, on April 3rd, 2017

2017-02-28 - 17:45

Genticel becomes “Genkyotex”: Genticel’s General Meeting approves the strategic combination with GenKyoTex SA

2017-02-28 - 08:30

2016 annual results

2017-01-31 - 20:30

Registration of Document E pertaining to the planned strategic combination between Genticel and Genkyotex

2017-01-30 - 18:00

BUSINESS UPDATE - FOURTH QUARTER 2016

2017-01-25 - 18:00

GENTICEL ANNOUNCES ITS FINANCIAL CALENDAR FOR 2017

2017-01-03 - 18:00

SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

2017-01-03 - 18:00

Disclosure of the total number of voting rights and shares composing the share capital

2016-12-22 - 13:00

Genticel and Genkyotex Announce Intention to Enter into Strategic Combination

2016-12-13 - 18:30

GENTICEL REPORTS FINAL RESULTS OF GTL001 PHASE 2 TRIAL IN HPV16/18-INFECTED WOMEN

2016-11-30 - 08:00

GENTICEL successfully completes determining milestone in partnership with Serum Institute regarding use of GTL003 in multivalent vaccines

2016-10-27 - 19:35

BUSINESS UPDATE - THIRD QUARTER 2016

2016-09-22 - 20:00

GENTICEL PRESENTS FIRST HALF 2016 FINANCIAL RESULTS AND UPDATES ITS OPERATIONAL OUTLOOK

2016-08-08 - 19:35

Disclosure of the total number of voting rights and shares composing the share capital

2016-08-08 - 19:35

HALF-YEAR SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

2016-07-28 - 19:35

BUSINESS UPDATE - SECOND QUARTER 2016

2016-07-07 - 20:30

Disclosure of the total number of voting rights and shares composing the share capital

2016-07-06 - 19:35

GENTICEL APPOINTS EUMEDIX AS STRATEGIC ADVISOR TO SUPPORT COMPANY'S ACCESS TO INNOVATIVE DRUG CANDIDATES

2016-06-23 - 18:45

GENTICEL REPORTS 18 MONTH INTERIM ANALYSIS OF GTL001 PHASE 2 TRIAL IN HPV16/18 INFECTED WOMEN

2016-06-15 - 20:30

GENTICEL TO PRESENT CLINICAL RESULTS OF GTL001 AND PRECLINICAL RESULTS OF GTL002 AT EUROGIN 2016 CONGRESS IN SALZBURG, AUSTRIA

2016-06-13 - 19:35

GENTICEL ANNOUNCES COMPLETION OF TWO MAJOR MILESTONES IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

2016-06-08 - 19:35

Disclosure of the total number of voting rights and shares composing the share capital

2016-06-01 - 20:00

GENTICEL ANNOUNCES PUBLICATION IN 'CLINICAL CANCER RESEARCH' OF PHASE 1 TRIAL RESULTS SUPPORTING SAFETY, TOLERABILITY AND IMMUNOGENICITY OF GTL001

2016-05-11 - 09:00

Disclosure of the total number of voting rights and shares composing the share capital

2016-04-28 - 19:35

BUSINESS UPDATE - FIRST QUARTER 2016

2016-04-26 - 19:35

PUBLICATION OF THE 2015 ANNUAL FINANCIAL REPORT

2016-04-21 - 20:45

PUBLICATION OF THE FIRST ISSUE OF GENTICEL'S SHAREHOLDER NEWSLETTER

2016-04-20 - 19:30

GENTICEL REPORTS ADDITIONAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

2016-04-06 - 19:00

Disclosure of the total number of voting rights and shares composing the share capital

2016-03-14 - 07:00

GENTICEL ANNOUNCES 2015 ANNUAL RESULTS AND STRATEGIC UPDATE FOR 2016

2016-03-10 - 18:30

GENTICEL UPDATES ITS FINANCIAL CALENDAR FOR 2016 AND ANNOUNCES PARTICIPATION IN KEY CONFERENCES IN H1 2016

2016-01-27 - 18:40

GENTICEL REPORTS INITIAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

2016-01-25 - 18:00

BUSINESS UPDATE - FOURTH QUARTER 2015

2016-01-11 - 08:30

GENTICEL ANNOUNCES ITS FINANCIAL CALENDAR FOR 2016

2016-01-07 - 18:00

SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

2016-01-07 - 18:00

Disclosure of the total number of voting rights and shares composing the share capital

2016-01-07 - 07:30

GENTICEL TO EVALUATE ROCHE MOLECULAR SYSTEMS' COBAS® HPV TEST IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

2016-01-05 - 19:00

Genticel appoints Rémi Palmantier, PhD, as Chief Scientific Officer to accelerate its development